Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted therapies for Diffuse Intrinsic Pontine Glioma (DIPG)
NCT02233049Phase 2Unknown
- Sponsor
- Gustave Roussy
- Start
- Oct 2014
- Primary completion
- Oct 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, everolimus, dasatinib in diffuse intrinsic pontine glioma (DIPG), sponsored by Gustave Roussy. Status: unknown.
02
Drugs
erlotinibeverolimusdasatinib
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT02233049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02233049.